

Mark E Molitch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6459374/publications.pdf>

Version: 2024-02-01

172
papers

19,114
citations

18482

62
h-index

11607

135
g-index

179
all docs

179
docs citations

179
times ranked

15515
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. American Journal of Kidney Diseases, 2022, 79, 728-736.	1.9	23
2	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593.	8.6	1
3	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology, 2022, 10, 102-111.	11.4	23
4	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases, 2022, 79, 457-479.	1.9	18
5	Glucocorticoid receptor blockers. Pituitary, 2022, 25, 733-736.	2.9	10
6	A Pituitary Society update to acromegaly management guidelines. Pituitary, 2021, 24, 1-13.	2.9	158
7	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
8	Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. Frontiers in Endocrinology, 2021, 12, 627711.	3.5	18
9	Prolactin and Other Pituitary Disorders in Kidney Disease. Seminars in Nephrology, 2021, 41, 156-167.	1.6	9
10	A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. Journal of the Endocrine Society, 2021, 5, A517-A517.	0.2	3
11	Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. Journal of the Endocrine Society, 2021, 5, A518-A519.	0.2	2
12	Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial. Journal of the Endocrine Society, 2021, 5, A522-A523.	0.2	0
13	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. Journal of the Endocrine Society, 2021, 5, A527-A528.	0.2	1
14	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology, 2021, 9, 847-875.	11.4	315
15	Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. Growth Hormone and IGF Research, 2020, 50, 71-82.	1.1	8
16	An evaluation of recurrent hypoglycemia across Chicago, Illinois. Journal of Diabetes and Its Complications, 2020, 34, 107685.	2.3	0
17	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
18	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3785-e3797.	3.6	54

#	ARTICLE	IF	CITATIONS
19	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	27.0	228
20	Dopamine agonists and antipsychotics. <i>European Journal of Endocrinology</i> , 2020, 183, C11-C13.	3.7	13
21	Exercise based assessment of cardiac autonomic function in type 1 versus type 2 diabetes mellitus. <i>Cardiology Journal</i> , 2020, , .	1.2	1
22	Rebuttals to “The Debate on Insulin vs. Non-insulin Use in the Hospital Setting” Continued Use of Insulin or Time to Revise the Guidelines? <i>Current Diabetes Reports</i> , 2019, 19, 66.	4.2	0
23	Pregnancy and Endocrine Disorders. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, xv-xvi.	3.2	1
24	Use of Insulin in the Inpatient Setting: Need for Continued Use. <i>Current Diabetes Reports</i> , 2019, 19, 64.	4.2	3
25	Pituitary Tumors in Pregnancy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 569-581.	3.2	42
26	Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6238-6246.	3.6	20
27	Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. <i>Physiological Reports</i> , 2019, 7, e14242.	1.7	10
28	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 854-861.	4.5	37
29	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol “Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	8.6	39
30	Prolactin and Pregnancy. <i>Contemporary Endocrinology</i> , 2019, , 161-174.	0.1	1
31	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 883-890.	8.6	76
32	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	3.6	305
33	Other Pituitary Disorders and Kidney Disease. , 2019, , 309-320.		0
34	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 681-688.	3.6	79
35	Management of nonfunctioning pituitary adenomas (NFAs): observation. <i>Pituitary</i> , 2018, 21, 162-167.	2.9	41
36	Excellence in the treatment of patients with pituitary tumors. <i>Pituitary</i> , 2018, 21, 107-107.	2.9	4

#	ARTICLE	IF	CITATIONS
37	Development of a Predictive Model for Hyperglycemia in Nondiabetic Recipients After Liver Transplantation. <i>Transplantation Direct</i> , 2018, 4, e393.	1.6	1
38	Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2018, 2, 1314-1319.	0.2	12
39	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 879-890.	11.4	64
40	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	2.3	14
41	Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. <i>Endocrine</i> , 2018, 61, 105-117.	2.3	5
42	Validation of data from electronic data warehouse in diabetic ketoacidosis: Caution is needed. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 650-654.	2.3	17
43	New Onset Diabetes After Transplant: Data from the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>American Journal of Medicine</i> , 2018, 131, e347.	1.5	1
44	Lessons From the Testosterone Trials. <i>Endocrine Reviews</i> , 2018, 39, 369-386.	20.1	173
45	Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-3279.	3.6	24
46	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 708.	7.4	289
47	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 717.	7.4	179
48	Association of Testosterone Levels With Anemia in Older Men. <i>JAMA Internal Medicine</i> , 2017, 177, 480.	5.1	180
49	Diagnosis and Treatment of Pituitary Adenomas. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 516.	7.4	684
50	Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. <i>Diabetologia</i> , 2017, 60, 1601-1611.	6.3	129
51	A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. <i>Pituitary</i> , 2017, 20, 605-618.	2.9	10
52	Evaluation of Outcomes and Complications in Patients Who Experience Hypoglycemia After Cardiac Surgery. <i>Endocrine Practice</i> , 2017, 23, 46-55.	2.1	7
53	Pituitary and Adrenal Disorders in Pregnancy. , 2017, , 938-946.		0
54	Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels. <i>Pituitary</i> , 2016, 19, 601-604.	2.9	7

#	ARTICLE	IF	CITATIONS
55	An Evaluation of Recurrent Diabetic Ketoacidosis, Fragmentation of Care, and Mortality Across Chicago, Illinois. <i>Diabetes Care</i> , 2016, 39, 1671-1676.	8.6	64
56	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	4.5	93
57	Inpatient Hypoglycemic Events in a Comparative Effectiveness Trial for Glycemic Control in a High-Risk Population. <i>Endocrine Practice</i> , 2016, 22, 1040-1047.	2.1	6
58	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?. <i>Diabetes Care</i> , 2016, 39, 1287-1291.	8.6	27
59	Osilodrostat, a potent oral 11 β -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. <i>Pituitary</i> , 2016, 19, 138-148.	2.9	116
60	Diabetes Care After Transplant. <i>Medical Clinics of North America</i> , 2016, 100, 535-550.	2.5	39
61	Effects of Testosterone Treatment in Older Men. <i>New England Journal of Medicine</i> , 2016, 374, 611-624.	27.0	675
62	Hormonal Changes and Endocrine Testing in Pregnancy. , 2016, , 2530-2546.e4.		0
63	Recruitment and Screening for the Testosterone Trials. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1105-1111.	3.6	28
64	Management of diabetes mellitus in patients with chronic kidney disease. <i>Clinical Diabetes and Endocrinology</i> , 2015, 1, 2.	2.7	88
65	Enlarged Thymus in a Patient With Dyspnea and Weight Loss. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2174.	7.4	1
66	What Does This Retina Examination Show?. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2555.	7.4	0
67	Diabetic Kidney Disease: Much Progress, But Still More to Do. <i>Diabetes Spectrum</i> , 2015, 28, 154-156.	1.0	2
68	Current approaches to the pharmacological management of Cushing's disease. <i>Molecular and Cellular Endocrinology</i> , 2015, 408, 185-189.	3.2	15
69	ENDOCRINOLOGY IN PREGNANCY: Management of the pregnant patient with a prolactinoma. <i>European Journal of Endocrinology</i> , 2015, 172, R205-R213.	3.7	129
70	Cross-Disciplinary Biomarkers Research. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 894-902.	4.5	24
71	We stand upon the shoulders of giants!. <i>Pituitary</i> , 2015, 18, 417-430.	2.9	0
72	Letter to the Editor: Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L98-L98.	3.6	2

#	ARTICLE	IF	CITATIONS
73	Prolactin in Human Reproduction. , 2014, , 45-65.e11.		5
74	Examination of Implementation of Intravenous and Subcutaneous Insulin Protocols and Glycemic Control in Heart Transplant Patients. Endocrine Practice, 2014, 20, 527-535.	2.1	12
75	The Authors Reply:. Kidney International, 2014, 86, 1270.	5.2	0
76	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	1.6	98
77	Insulin Therapy for Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 2315.	7.4	121
78	Management of medically refractory prolactinoma. Journal of Neuro-Oncology, 2014, 117, 421-428.	2.9	130
79	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818.	6.1	40
80	Acromegaly: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3933-3951.	3.6	1,312
81	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. American Journal of Kidney Diseases, 2014, 64, 510-533.	1.9	439
82	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 2014, 37, 2864-2883.	8.6	781
83	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350.	6.1	76
84	Nonfunctioning pituitary tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 167-184.	1.8	48
85	Surgical treatment of prolactinomas: cons. Endocrine, 2014, 47, 730-733.	2.3	26
86	Comparison of Glycemic and Surgical Outcomes After Change in Glycemic Targets in Cardiac Surgery Patients. Diabetes Care, 2014, 37, 2960-2965.	8.6	20
87	Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga. Diabetes Care, 2014, 37, 867-875.	8.6	151
88	Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clinical Transplantation, 2013, 27, 444-454.	1.6	20
89	A New Therapeutic Approach in the Medical Treatment of Cushing's SYNDROME: GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE. Endocrine Practice, 2013, 19, 313-326.	2.1	53
90	Current state of type 2 diabetes management. American Journal of Managed Care, 2013, 19, S136-42.	1.1	7

#	ARTICLE	IF	CITATIONS
91	Anterior Pituitary. , 2012, , 1431-1444.		1
92	Atypical Antipsychotics and Pituitary Tumors. Journal of Clinical Psychopharmacology, 2012, 32, 741-742.	1.4	2
93	A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency. Diabetes Care, 2012, 35, 1970-1974.	8.6	85
94	Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2039-2049.	3.6	409
95	Tumors invading the cavernous sinus that cause internal carotid artery compression are rarely pituitary adenomas. Pituitary, 2012, 15, 598-600.	2.9	21
96	Management of Incidentally Found Nonfunctional Pituitary Tumors. Neurosurgery Clinics of North America, 2012, 23, 543-553.	1.7	26
97	Neuroendocrinology and the Neuroendocrine System. , 2012, , 1425-1431.		1
98	Cabergoline versus bromocriptine: a meta-analysis?. Nature Reviews Endocrinology, 2011, 7, 254-255.	9.6	6
99	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine, 2011, 365, 2366-2376.	27.0	507
100	Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 894-904.	3.6	452
101	Prolactinoma in pregnancy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 885-896.	4.7	96
102	Glycemic Control by A Glucose Management Service and Infection Rates After Liver Transplantation. Endocrine Practice, 2011, 17, 546-551.	2.1	37
103	Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas. Endocrine Practice, 2011, 17, e55-e58.	2.1	20
104	Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus. Pituitary, 2011, 14, 194-197.	2.9	21
105	Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1587-1609.	3.6	723
106	Prolactin. , 2011, , 119-166.		4
107	Prolactinoma. , 2011, , 475-531.		7
108	Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria_{title};An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort_{title};<alt-title>;Microalbuminuria Outcomes in Type 1 Diabetes</alt-title>; Archives of Internal Medicine, 2011, 171, 412.	3.8	298

#	ARTICLE	IF	CITATIONS
109	Posttransplant Hyperglycemia is Associated With Increased Risk of Liver Allograft Rejection. Transplantation, 2010, 89, 222-226.	1.0	76
110	The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary, 2010, 13, 266-286.	2.9	8
111	Prolactinomas and pregnancy. Clinical Endocrinology, 2010, 73, 147-148.	2.4	22
112	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2010, 33, 1536-1543.	8.6	257
113	Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1235-1242.	4.5	46
114	Diabetes, Cardiovascular Risk and Nephropathy. Cardiology Clinics, 2010, 28, 467-475.	2.2	26
115	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine, 2009, 360, 2503-2515.	27.0	1,705
116	Pituitary radiotherapy. Pituitary, 2009, 12, 1-2.	2.9	6
117	Pituitary incidentalomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 667-675.	4.7	139
118	Prolactin in Human Reproduction. , 2009, , 57-78.		9
119	Drugs and prolactin. Pituitary, 2008, 11, 209-218.	2.9	140
120	Insulin resistance following cardiothoracic surgery in patients with and without a preoperative diagnosis of type 2 diabetes during treatment with intravenous insulin therapy for postoperative hyperglycemia. Journal of Diabetes and Its Complications, 2008, 22, 229-234.	2.3	14
121	Lanreotide Autogel?? in the Management of Acromegaly. Drugs, 2008, 68, 724.	10.9	7
122	Nonfunctioning Pituitary Tumors and Pituitary Incidentalomas. Endocrinology and Metabolism Clinics of North America, 2008, 37, 151-171.	3.2	146
123	The Cabergoline-Resistant Prolactinoma Patient: New Challenges. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4643-4645.	3.6	39
124	The Patient with prolactinoma. Reproductive Medicine and Assisted Reproductive Techniques Series, 2008, , 179-190.	0.1	0
125	Pituitary Tumors and Pregnancy. , 2008, , 377-398.		0
126	Reduction of Surgical Mortality and Morbidity in Diabetic Patients Undergoing Cardiac Surgery With a Combined Intravenous and Subcutaneous Insulin Glucose Management Strategy. Diabetes Care, 2007, 30, 823-828.	8.6	191

#	ARTICLE	IF	CITATIONS
127	Guías de la Pituitary Society para el diagnóstico y tratamiento de los prolactinomas. Endocrinología Y Nutrición: Organó De La Sociedad Espanola De Endocrinología Y Nutrición, 2007, 54, 438.e1-438.e10.	0.8	1
128	Lymphocytic Hypophysitis. Hormone Research in Paediatrics, 2007, 68, 145-150.	1.8	45
129	Pituitary Disorders During Pregnancy. Endocrinology and Metabolism Clinics of North America, 2006, 35, 99-116.	3.2	62
130	Inpatient Management of Hyperglycemia: The Northwestern Experience. Endocrine Practice, 2006, 12, 491-505.	2.1	96
131	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 2006, 65, 265-273.	2.4	720
132	Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1621-1634.	3.6	396
133	Advances in the Treatment of Prolactinomas. Endocrine Reviews, 2006, 27, 485-534.	20.1	707
134	Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1090-1099.	4.5	54
135	Prolactin-secreting tumors: what's new?. Expert Review of Anticancer Therapy, 2006, 6, S29-S35.	2.4	16
136	Higher Levels of HDL Cholesterol Are Associated With a Decreased Likelihood of Albuminuria in Patients With Long-Standing Type 1 Diabetes. Diabetes Care, 2006, 29, 78-82.	8.6	91
137	Pharmacologic Resistance in Prolactinoma Patients. Pituitary, 2005, 8, 43-52.	2.9	176
138	The Pituitary Mass: Diagnosis and Management. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 55-62.	5.7	24
139	The incidence of Sheehan's syndrome after obstetric hemorrhage. Fertility and Sterility, 2005, 84, 975-979.	1.0	62
140	Medication-Induced Hyperprolactinemia. Mayo Clinic Proceedings, 2005, 80, 1050-1057.	3.0	227
141	Diabetes and Hypertension: Pathogenesis, Prevention and Treatment. Clinical and Experimental Hypertension, 2004, 26, 621-628.	1.3	84
142	Cortisol levels and mortality in severe sepsis. Clinical Endocrinology, 2004, 60, 29-35.	2.4	125
143	Prolactinoma, Diagnosis. , 2004, , 114-117.		0
144	Dopamine resistance of prolactinomas. Pituitary, 2003, 6, 19-27.	2.9	91

#	ARTICLE	IF	CITATIONS
145	Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile. Pituitary, 2003, 6, 5-10.	2.9	11
146	Pituitary tumors and pregnancy. Growth Hormone and IGF Research, 2003, 13, S38-S44.	1.1	88
147	The Diabetes Prevention Program and Its Global Implications. Journal of the American Society of Nephrology: JASN, 2003, 14, S103-S107.	6.1	46
148	The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4447-4451.	3.6	91
149	The relationship between glucose control and the development and progression of diabetic nephropathy. Current Diabetes Reports, 2002, 2, 523-529.	4.2	26
150	Medical management of prolactin-secreting pituitary adenomas. Pituitary, 2002, 5, 55-65.	2.9	96
151	Lymphocytic Hypophysitis. Growth Hormone, 2001, , 131-148.	0.2	58
152	Prolactinomas. Growth Hormone, 2001, , 81-99.	0.2	1
153	DISORDERS OF PROLACTIN SECRETION. Endocrinology and Metabolism Clinics of North America, 2001, 30, 585-610.	3.2	149
154	Rise in Albuminuria and Blood Pressure in Patients Who Progressed to Diabetic Nephropathy in the Diabetes Control and Complications Trial. Journal of the American Society of Nephrology: JASN, 2001, 12, 333-340.	6.1	24
155	MEDICAL TREATMENT OF PROLACTINOMAS. Endocrinology and Metabolism Clinics of North America, 1999, 28, 143-169.	3.2	143
156	Postoperative Radiotherapy for Clinically Nonfunctioning Pituitary Adenomas. , 1998, 8, 71-78.		9
157	PITUITARY INCIDENTALOMAS. Endocrinology and Metabolism Clinics of North America, 1997, 26, 725-740.	3.2	73
158	Effects of Calcium Channel Blockade with Verapamil on the Prolactin Response to TRH, L-Dopa, and Bromocriptine. American Journal of the Medical Sciences, 1992, 304, 289-293.	1.1	12
159	Pathologic Hyperprolactinemia. Endocrinology and Metabolism Clinics of North America, 1992, 21, 877-901.	3.2	115
160	Clinical Manifestations of Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 597-614.	3.2	181
161	Unaltered Drug Metabolizing Enzyme Systems in Type II Diabetes Mellitus Before and During Glyburide Therapy. Journal of Clinical Pharmacology, 1990, 30, 943-947.	2.0	9
162	Effect of Angiotensin-Converting Enzyme Inhibition on Pituitary Hormone Responses to Insulin-Induced Hypoglycemia in Humans*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 256-259.	3.6	13

#	ARTICLE	IF	CITATIONS
163	CV 205â€“502 Treatment of Hyperprolactinemia*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 336-339.	3.6	62
164	Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 698-705.	3.6	421
165	Pregnancy and the Hyperprolactinemic Woman. New England Journal of Medicine, 1985, 312, 1364-1370.	27.0	250
166	Hyperprolactinemia in Patients With Renal Insufficiency and Chronic Renal Failure Requiring Hemodialysis or Chronic Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1985, 6, 245-249.	1.9	112
167	Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency. American Journal of Medicine, 1985, 79, 271-276.	1.5	51
168	Cavernous sinus syndrome due to prolactinoma: Resolution with bromocriptine. World Neurosurgery, 1983, 19, 280-284.	1.3	21
169	Hyperprolactinemic disorders. Disease-a-Month, 1982, 28, 6-58.	1.1	18
170	Is prolactin secreted ectopically?. American Journal of Medicine, 1981, 70, 803-807.	1.5	35
171	Galactorrhea, Oligo/Amenorrhea, and Hyperprolactinemia in Patients with Craniopharyngiomas*. Journal of Clinical Endocrinology and Metabolism, 1980, 51, 798-800.	3.6	52
172	Eosinophilic Granuloma Mimicking a Pituitary Tumor. Neurosurgery, 1979, 5, 723-725.	1.1	23